share_log

UBS Downgrades RAPT Therapeutics to Neutral, Lowers Price Target to $10

Benzinga ·  Feb 22 20:37

UBS analyst Eliana Merle downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral and lowers the price target from $61 to $10.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment